TALE Protein Scaffolds with Specific Mutations for Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Standard TALE protein constructs for gene therapy do not consistently meet the required specificity and efficiency levels, often resulting in off-target binding and reduced catalytic activity, which poses challenges for therapeutic safety.
Innovation Solution
The design of new TALE scaffolds with specific mutations in the AvrBs3 repeats, combined with C-terminal and N-terminal sequences, enhances the specificity and activity of TALE fusion proteins by improving the interaction with target sequences while maintaining catalytic domain flexibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard TALE protein constructs are used for gene therapy, then the basic function of targeting genomic sequences is achieved, but the specificity and efficiency levels are insufficient, resulting in off-target binding and reduced catalytic activity
Solution Approach 1:
The patent applies local quality by introducing specific mutations at defined positions within the TALE repeat structure. The mutations are localized to positions 3, 4, 12, 13, 32, and 33 of the repeat unit, with specific amino acid substitutions (e.g., position 3 to Y/S, position 4 to Q/N, position 12 to Q/N, position 13 to H/Q/N, position 32 to Q/N, position 33 to H/Q/N). These localized changes improve on-target binding specificity while minimizing off-target effects, resolving the contradiction between basic functionality and high reliability.
2Reliability
If TALE proteins are designed with higher specificity through mutations, then on-target/off-target activity ratios improve, but the complexity of protein design and construction increases
Solution Approach 1:
The patent employs parameter changes by systematically modifying amino acid residues at specific positions within the TALE repeat unit. The defined mutation patterns (positions 3, 4, 12, 13, 32, 33 with specific amino acid substitutions) create a standardized framework that improves binding specificity while providing a reproducible design protocol. This structured approach to parameter modification balances improved reliability with manageable design complexity.
Data Source
AI summary
The present invention relates to the design of improved TALE protein fusions useful as sequence-specific genomic reagents, such as TALE-nucleases and TALE base editors, displaying higher on-target/off-target activity ratios. Its goal is to produce safer reagents to genetically modify the genomes of different types of cells, especially mammalian cells, in particular for their use in gene therapy.